How Much Is Mounjaro Without Insurance? Tirzepatide Cost Breakdown

What Mounjaro Actually Costs at the Pharmacy Counter

Without insurance, a single 4-pen carton of Mounjaro runs between $1,023 and $1,462 at most U.S. Retail pharmacies, based on the wholesale acquisition cost (WAC) published by Eli Lilly [1]. The exact amount depends on your prescribed dose and the pharmacy's markup. Cash-pay patients typically see the highest prices.

List Price by Dose Tier

Eli Lilly sets the same WAC for all Mounjaro dose strengths within a given package size. Each carton contains four single-dose pens, representing one month of weekly injections. The listed WAC as of early 2026 sits at approximately $1,023.04 per carton for the diabetes indication [1]. Pharmacy dispensing fees, regional pricing differences, and markup practices mean the price you see at checkout can climb above that figure. GoodRx and similar aggregators report cash prices ranging from roughly $1,050 to $1,200 at major chains like CVS, Walgreens, and Walmart [2].

Why the Price Keeps Rising

Eli Lilly raised Mounjaro's list price twice during its first 18 months on the market. Pharmaceutical price increases in the GLP-1 receptor agonist class have tracked well above the consumer price index. The Institute for Clinical and Economic Review (ICER) estimated a health-benefit-based price benchmark for tirzepatide at $9,000 to $13,800 per year for type 2 diabetes, which translates to $750 to $1,150 monthly [3]. The current list price sits near or above the top end of that range.

How Tirzepatide Pricing Compares to Other GLP-1 Medications

Mounjaro is not the most expensive GLP-1 on the market, but it is far from cheap. Semaglutide (Wegovy) carries a list price around $1,349 per month for weight management [4]. Ozempic, the diabetes-indication brand of semaglutide, lists near $936 monthly [4]. Liraglutide (Saxenda) sits at approximately $1,349 for the 3 mg daily dose [5].

Price-Per-Efficacy Considerations

Raw price comparisons miss a key variable: clinical effect size. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo [6]. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg achieved 14.9% weight loss over 68 weeks [7]. On a cost-per-percentage-point-of-weight-loss basis, tirzepatide delivers more weight reduction per dollar at equivalent list prices.

Branded vs. Compounded Tirzepatide

Since the FDA placed tirzepatide on its drug shortage list in late 2023, 503A and 503B compounding pharmacies have legally produced compounded versions. Prices for compounded tirzepatide through telehealth platforms typically range from $200 to $550 per month [8]. The FDA has signaled that compounded versions must exit the market once the shortage is formally resolved, making this a time-limited option. Patients considering compounded tirzepatide should confirm their pharmacy holds valid state and federal registrations.

The Lilly Mounjaro Savings Card and Other Discount Programs

Eli Lilly operates a manufacturer savings program that can cut monthly costs dramatically for patients with qualifying commercial insurance. The card is not available to patients enrolled in Medicare, Medicaid, TRICARE, or other federal or state healthcare programs [1].

How the Savings Card Works

Eligible patients with commercial insurance pay as little as $25 per monthly prescription fill. Lilly covers the remaining copay or coinsurance up to a maximum benefit per fill. The card resets annually and requires re-enrollment. Patients must have a valid prescription for a Mounjaro-approved indication (type 2 diabetes) to qualify for the branded card [1].

Cash-Pay Patients Without Any Insurance

For the roughly 27.6 million Americans who were uninsured as of the 2022 National Health Interview Survey [9], Mounjaro's full cash price represents an annual cost exceeding $12,000. Lilly does not currently extend the savings card to purely uninsured, cash-pay patients for Mounjaro. The Lilly Insulin Value Program and other patient assistance programs cover different products in Lilly's portfolio, but tirzepatide-specific patient assistance for uninsured individuals remains limited.

Pharmacy Discount Aggregators

GoodRx, RxSaver, and SingleCare sometimes surface negotiated cash prices below the published WAC. Discounts fluctuate by pharmacy and ZIP code. Reported savings through these platforms range from 5% to 15% off standard retail, bringing the monthly cost closer to $950 to $1,050 in some markets [2]. These are not insurance benefits and cannot be combined with the Lilly savings card.

What Drives the Out-of-Pocket Cost for Insured Patients

Even patients with insurance face variable and sometimes steep out-of-pocket expenses for Mounjaro. Coverage depends on the plan formulary, the prescribed indication, and whether the insurer requires prior authorization or step therapy.

Formulary Tier Placement

Most commercial insurers that cover Mounjaro place it on a specialty or non-preferred brand tier. A 2024 analysis by the Kaiser Family Foundation found that specialty-tier drugs carried average coinsurance rates of 26% to 33% across employer-sponsored plans [10]. Applied to Mounjaro's list price, that yields a monthly patient cost of $266 to $482 before any manufacturer coupon.

Prior Authorization and Step Therapy

The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for type 2 diabetes, or as first-line agents in patients with established atherosclerotic cardiovascular disease [11]. Many insurers still require documentation that metformin was tried first. Prior authorization approval rates for tirzepatide vary by plan, and denials add weeks of delay plus administrative burden on prescribers.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in a 2023 interview: "Cost remains the single greatest barrier to access for GLP-1 receptor agonists, and patients with the most to gain from these therapies are often the ones least able to afford them" [11].

The Medicare Coverage Gap

Medicare Part D does not cover Mounjaro for weight loss (the Zepbound indication), and coverage for the type 2 diabetes indication varies by plan. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, which took effect in 2025, helps some Medicare beneficiaries [12]. For a drug priced above $12,000 per year, the cap means patients hit their maximum out-of-pocket spending within the first few months, after which coverage kicks in.

Strategies to Lower Your Mounjaro Costs

Several practical approaches can reduce what you pay each month, depending on your insurance status and medical situation.

Ask Your Prescriber About Samples

Eli Lilly distributes starter samples of Mounjaro to physician offices. Samples can cover the first one to two months of the titration period (2.5 mg and 5 mg doses), which allows patients to confirm tolerability before committing to ongoing costs [1].

Compare Pharmacy Prices Actively

Retail price variation for Mounjaro across pharmacies in the same city can exceed $100 per fill. Costco pharmacies, which do not require a membership for prescription pickups in most states, sometimes offer lower prices than chain pharmacies. Independent pharmacies with access to group purchasing organizations may also undercut national chains.

Explore Clinical Trials

ClinicalTrials.gov lists active tirzepatide studies, some of which provide the medication at no cost to participants. The SURPASS and SURMOUNT trial programs enrolled thousands of patients across the U.S. [6]. New studies evaluating tirzepatide for indications like heart failure with preserved ejection fraction (SUMMIT trial) and obstructive sleep apnea are ongoing [13].

Consider the Zepbound Indication

Zepbound is the same molecule (tirzepatide) approved specifically for chronic weight management. Lilly has offered a separate Zepbound savings program with different eligibility criteria and pricing. Some patients find that switching the indication and brand name on their prescription changes their coverage status, though this depends entirely on plan formulary design.

Clinical Value Behind the Price Tag

The high price of Mounjaro reflects real clinical differentiation. Tirzepatide is the first dual GIP/GLP-1 receptor agonist to reach the market, and its efficacy data across the SURPASS (diabetes) and SURMOUNT (obesity) trial programs are the strongest recorded for any injectable in either indication.

Weight Loss and Glycemic Outcomes

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46% from baseline versus 1.86% for semaglutide 1 mg at 40 weeks [14]. That 0.6 percentage point difference is clinically meaningful. The same trial showed 13.1% body weight reduction with tirzepatide 15 mg versus 6.7% with semaglutide 1 mg [14].

Dr. Ania Jastreboff, Director of the Yale Obesity Research Center, noted at the 2023 American Diabetes Association Scientific Sessions: "Tirzepatide has shifted what we consider achievable with pharmacotherapy alone. We are now seeing weight reductions that were previously only possible with bariatric surgery" [6].

Cardiovascular and Metabolic Benefits

The SURMOUNT-MMO trial is evaluating tirzepatide's effect on major adverse cardiovascular events in adults with obesity and established cardiovascular disease [13]. Interim data from SURMOUNT-2 (N=938) showed that tirzepatide reduced body weight by 14.7% (15 mg) in adults with obesity and type 2 diabetes at 72 weeks, while also producing significant improvements in blood pressure, triglycerides, and inflammatory markers [15].

Cost-Effectiveness Analyses

ICER's 2024 updated assessment concluded that tirzepatide at its current net price (after rebates) falls within the range of cost-effectiveness for type 2 diabetes at a willingness-to-pay threshold of $150,000 per quality-adjusted life year [3]. For obesity without diabetes, the analysis was less favorable at list price, underscoring the importance of insurance coverage and discount programs for the weight management indication.

When Generic Tirzepatide Might Arrive

Eli Lilly holds composition-of-matter patents on tirzepatide that extend into the mid-2030s. No abbreviated new drug application (ANDA) for a generic version has been filed with the FDA as of May 2026. Biosimilar pathways do not apply because tirzepatide is a synthetic peptide manufactured through chemical synthesis, not a biologic [1].

Patent Field

The core tirzepatide patent (US Patent No. 10,980,841) lists an expiration date in 2036. Additional formulation and method-of-use patents could extend market exclusivity further. Paragraph IV challenges from generic manufacturers have not materialized publicly.

International Price Benchmarks

In Germany, where reference pricing applies, tirzepatide launched at roughly 30% below the U.S. List price. In Japan, where Mounjaro was approved in 2022 for type 2 diabetes, monthly treatment costs under the national health insurance system sit near the equivalent of $300 to $400 USD after patient cost-sharing [16]. These international benchmarks illustrate how much of the U.S. Price burden reflects the American pharmaceutical pricing structure rather than inherent manufacturing costs.

Tirzepatide's global manufacturing cost has been estimated at $5 to $20 per monthly dose by researchers at the University of Liverpool, based on active pharmaceutical ingredient synthesis costs and device packaging [16].